BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 28232049)

  • 1. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
    Lai X; Wang M; McElyea SD; Sherman S; House M; Korc M
    Cancer Lett; 2017 May; 393():86-93. PubMed ID: 28232049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma.
    Nakamura S; Sadakari Y; Ohtsuka T; Okayama T; Nakashima Y; Gotoh Y; Saeki K; Mori Y; Nakata K; Miyasaka Y; Onishi H; Oda Y; Goggins M; Nakamura M
    Ann Surg Oncol; 2019 Jul; 26(7):2104-2111. PubMed ID: 30820789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal glypican-1 discriminates pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Moutinho-Ribeiro P; Adem B; Batista I; Silva M; Silva S; Ruivo CF; Morais R; Peixoto A; Coelho R; Costa-Moreira P; Lopes S; Vilas-Boas F; Durães C; Lopes J; Barroca H; Carneiro F; Melo SA; Macedo G
    Dig Liver Dis; 2022 Jul; 54(7):871-877. PubMed ID: 34840127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
    Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
    Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
    Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
    Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
    Castillo J; Bernard V; San Lucas FA; Allenson K; Capello M; Kim DU; Gascoyne P; Mulu FC; Stephens BM; Huang J; Wang H; Momin AA; Jacamo RO; Katz M; Wolff R; Javle M; Varadhachary G; Wistuba II; Hanash S; Maitra A; Alvarez H
    Ann Oncol; 2018 Jan; 29(1):223-229. PubMed ID: 29045505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.
    Cote GA; Gore AJ; McElyea SD; Heathers LE; Xu H; Sherman S; Korc M
    Am J Gastroenterol; 2014 Dec; 109(12):1942-52. PubMed ID: 25350767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosome-encapsulated microRNA-4525, microRNA-451a and microRNA-21 in portal vein blood is a high-sensitive liquid biomarker for the selection of high-risk pancreatic ductal adenocarcinoma patients.
    Kawamura S; Iinuma H; Wada K; Takahashi K; Minezaki S; Kainuma M; Shibuya M; Miura F; Sano K
    J Hepatobiliary Pancreat Sci; 2019 Feb; 26(2):63-72. PubMed ID: 30561106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma.
    Que R; Ding G; Chen J; Cao L
    World J Surg Oncol; 2013 Sep; 11():219. PubMed ID: 24007214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma.
    Yu S; Li Y; Liao Z; Wang Z; Wang Z; Li Y; Qian L; Zhao J; Zong H; Kang B; Zou WB; Chen K; He X; Meng Z; Chen Z; Huang S; Wang P
    Gut; 2020 Mar; 69(3):540-550. PubMed ID: 31562239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
    Akamatsu M; Makino N; Ikeda Y; Matsuda A; Ito M; Kakizaki Y; Saito Y; Ishizawa T; Kobayashi T; Furukawa T; Ueno Y
    PLoS One; 2016; 11(7):e0158669. PubMed ID: 27380024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
    Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
    Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
    Alemar B; Izetti P; Gregório C; Macedo GS; Castro MA; Osvaldt AB; Matte U; Ashton-Prolla P
    Pancreas; 2016 Jan; 45(1):84-92. PubMed ID: 26262588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma.
    Lu H; Niu F; Liu F; Gao J; Sun Y; Zhao X
    Cancer Med; 2017 Jun; 6(6):1181-1191. PubMed ID: 28440066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Guo S; Qin H; Liu K; Wang H; Bai S; Liu S; Shao Z; Zhang Y; Song B; Xu X; Shen J; Zeng P; Shi X; Chen H; Gao S; Xu J; Pan Y; Xiong L; Li F; Zhang D; Jiao X; Jin G
    Clin Transl Med; 2021 Sep; 11(9):e520. PubMed ID: 34586739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Exosomal GPC1, CD82, and Serum CA19-9 as Multiplex Targets: A Specific, Sensitive, and Reproducible Detection Panel for the Diagnosis of Pancreatic Cancer.
    Xiao D; Dong Z; Zhen L; Xia G; Huang X; Wang T; Guo H; Yang B; Xu C; Wu W; Zhao X; Xu H
    Mol Cancer Res; 2020 Feb; 18(2):300-310. PubMed ID: 31662449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study.
    Duell EJ; Lujan-Barroso L; Sala N; Deitz McElyea S; Overvad K; Tjonneland A; Olsen A; Weiderpass E; Busund LT; Moi L; Muller D; Vineis P; Aune D; Matullo G; Naccarati A; Panico S; Tagliabue G; Tumino R; Palli D; Kaaks R; Katzke VA; Boeing H; Bueno-de-Mesquita HBA; Peeters PH; Trichopoulou A; Lagiou P; Kotanidou A; Travis RC; Wareham N; Khaw KT; Ramon Quiros J; Rodríguez-Barranco M; Dorronsoro M; Chirlaque MD; Ardanaz E; Severi G; Boutron-Ruault MC; Rebours V; Brennan P; Gunter M; Scelo G; Cote G; Sherman S; Korc M
    Int J Cancer; 2017 Sep; 141(5):905-915. PubMed ID: 28542740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosomal glypican-1 is elevated in pancreatic cancer precursors and can signal genetic predisposition in the absence of endoscopic ultrasound abnormalities.
    Moutinho-Ribeiro P; Batista IA; Quintas ST; Adem B; Silva M; Morais R; Peixoto A; Coelho R; Costa-Moreira P; Medas R; Lopes S; Vilas-Boas F; Baptista M; Dias-Silva D; Esteves AL; Martins F; Lopes J; Barroca H; Carneiro F; Macedo G; Melo SA
    World J Gastroenterol; 2022 Aug; 28(31):4310-4327. PubMed ID: 36159010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.